Coherus Oncology Regains Compliance with Nasdaq Continued Listing Standards

Strategic Insights -

Coherus Oncology, Inc., a biopharmaceutical company, has regained compliance with the continued listing standards of the Nasdaq Global Market. The company received a deficiency notice from the Listing Qualifications Department on June 30, 2025, due to its common stock price falling below the minimum required bid price of $1.00 per share. However, after a 180-day grace period, Coherus Oncology's common stock price met the required minimum, and the company was notified by Nasdaq on September 5, 2025, that it had regained compliance with Listing Rule 5550(a)(2).

Key Takeaways:

  • Coherus Oncology received a deficiency notice on June 30, 2025, due to its common stock price falling below the minimum required bid price of $1.00 per share.
  • The company had a period of 180 calendar days, or until December 29, 2025, to regain compliance with the rule referred to in Listing Rule 5550(a)(2).
  • On September 5, 2025, the company received a letter from Nasdaq notifying it that the closing price of its common stock met the requisite period of time, and the matter was now closed.
  • The company is now in full compliance with all continued listing standards of the Nasdaq Global Market.
  • Dennis M. Lanfear, the Chief Executive Officer of Coherus Oncology, signed the report on September 8, 2025.

Statistics:

  • Number of days granted to Coherus Oncology to regain compliance: 180 calendar days
  • Date of deficiency notice: June 30, 2025
  • Date of Nasdaq notification: September 5, 2025
  • Deadline for compliance: December 29, 2025

Sources:

  • Form 8-K (Current Report) filed by Coherus Oncology, Inc. with the U.S. Securities and Exchange Commission on September 8, 2025.